OBJECTIVE: To determine whether a common single nucleotide polymorphism (SNP) in the ADRA1A gene encoding the α1A-adrenoceptor modifies the short- and long-term efficacy of α1-adrenoceptor antagonists in the treatment of benign prostatic hyperplasia (BPH). PATIENTS AND METHODS: For 254 patients with BPH and/or lower urinary tract symptoms who received α1-adrenergic antagonists for ≥3 months, the ADRA1A genotype at position 1475 of the coding region was determined. The patients' short-term response to treatment was determined for four outcome measures, i.e. the International Prostate Symptom Score (IPSS), the IPSS quality-of-life score, peak urinary flow rate, and obstruction grade, stratified by genotype. Eventual BPH-related invasive therapy was used as the outcome for assessing the long-term response to treatment. Genetic variants at positions 834, 896, 898 and 1831 were too rare to be considered in the analysis. RESULTS: There were no significant differences for the genotype strata in three of the four outcome measures. Patients with the CC genotype responded significantly better in quality-of-life perception than patients with the CT or TT genotype. There were also no significant differences in the risk of BPH-related invasive therapy among the three genotypes. CONCLUSIONS: The 1475C→T SNP in the ADRA1A gene does not modify the short- and long-term efficacy of α1- adrenoceptor antagonists for treating BPH. There was a small effect on perceived quality of life but this was not reflected in other variables that measured the treatment response more directly.
- Single nucleotide polymorphism
- α-adrenergic receptor